ANAPTYSBIO, INC. Form 10-KT: Transition report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-09-21: Form 10-KT; Period of report 2026-06-30; Description 10-KT; Document anab-20260630.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2026-09-21 | 10-KT | 2026-06-30 | 10-KT | anab-20260630.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |